Summary. Cannabis is legal in most states and a Schedule I controlled substance federally, and every legal question in the industry descends from that contradiction. A cannabis business pays federal income tax on gross profit rather than net income because § 280E disallows ordinary deductions. It generally cannot register a federal trademark for the goods it actually sells. It cannot file for bankruptcy. Its contracts may be unenforceable in federal court. This article explains how the industry operates within those constraints: the licensing and ownership disclosure rules determining who may participate, why banking access remains limited and what the FinCEN framework requires, how to build a defensible intellectual property position without federal registration, and what rescheduling would and would not change.

A cannabis retailer in a mature state market has an excellent year. Revenue of $8.4 million. Cost of goods sold of $4.1 million. Operating expenses — rent, payroll, security, marketing, compliance software, insurance, professional fees — of $3.6 million. Net income of $700,000.

Its federal taxable income is $4.3 million.

Not because anyone made an error. Because 26 U.S.C. § 280E provides that no deduction or credit shall be allowed for any amount paid or incurred in carrying on a trade or business consisting of trafficking in controlled substances within Schedule I or II. Cost of goods sold survives, because it is a reduction in gross receipts rather than a deduction and disallowing it would raise constitutional questions. Everything else does not.

At a 21 percent corporate rate, the company owes roughly $903,000 in federal tax on $700,000 of actual profit. Add state tax, and it lost money by operating profitably.

That is the defining economic fact of the American cannabis industry, and nearly every structural decision in it — entity choice, cost accounting, real estate, vertical integration, capital structure — is downstream of it.

The federal problem

Marijuana is a Schedule I controlled substance under 21 U.S.C. § 812, meaning federal law classifies it as having a high potential for abuse, no currently accepted medical use, and a lack of accepted safety under medical supervision. Cultivation, distribution, and possession are federal crimes, and Congress's power to prohibit them reaches purely intrastate activity. Gonzales v. Raich, 545 U.S. 1 (2005).

What restrains federal enforcement is not law but practice and appropriations.

The appropriations rider — variously the Rohrabacher-Farr, Rohrabacher-Blumenauer, or Joyce Amendment — prohibits the Department of Justice from spending funds to prevent states from implementing their medical marijuana laws. Courts have read it to bar prosecution of persons in strict compliance with state medical law. It must be renewed with each appropriations act, it has been, and it does not cover adult-use programs.

Enforcement policy. The 2013 Cole Memorandum set out federal enforcement priorities and effectively deprioritized state-compliant activity. It was rescinded in 2018 without a replacement, leaving discretion with United States Attorneys. As a practical matter, prosecutions of state-licensed operators in compliance with state law have been rare — but "rare" is not "unavailable," and the risk is real for operators who are not in compliance.

Rescheduling. The Department of Health and Human Services recommended moving marijuana to Schedule III, and the DEA initiated rulemaking. The proceeding has been protracted. What Schedule III would change: § 280E would no longer apply, because it reaches only Schedule I and II — the single largest economic change available to the industry. Research would become substantially easier. What it would not change: state-legal cannabis would remain federally unlawful, because Schedule III substances require FDA approval and a valid prescription dispensed through registered channels, which no state program contemplates. Banking would improve only at the margins. Interstate commerce would remain prohibited. Trademark registration would remain unavailable for most goods. Anyone modeling the effect of rescheduling should model the tax change and be skeptical of everything else.

Legislative proposals — the SAFE/SAFER Banking Act, the STATES Act, and various descheduling bills — have repeatedly passed one chamber or advanced in committee without becoming law. Plan for the current framework.

Licensing

Every state program is different, but the structural elements recur.

License types typically include cultivation (often tiered by canopy or plant count), manufacturing or processing (with separate authority for volatile solvent extraction), distribution, testing laboratories, retail dispensaries, delivery, microbusinesses, and in some states consumption lounges and event permits.

Limited licenses. Many states cap the number of licenses statewide or by county, and award them through competitive application processes scored on operational plans, security, community benefit, and — in a growing number of states — social equity criteria addressing prior cannabis convictions, residence in disproportionately impacted areas, and ownership by affected individuals. Where licenses are capped, the license itself becomes the principal asset, and the market for it drives most transaction activity in the state.

Ownership disclosure and suitability is the requirement most often underestimated. States require disclosure of every owner above a threshold (frequently 5 percent, sometimes any interest), every officer and director, and often every person with control however exercised — including through management agreements, debt with conversion features, or voting arrangements. Each disclosed person undergoes background checks, fingerprinting, and financial disclosure. Changes in ownership require prior approval, and closing a transaction before approval is a license violation in most states.

The practical consequences are severe for capital raising. A convertible note may confer control. A profits interest may be an ownership interest. A management agreement may make the manager a disclosable party. A fund investing across states may find that a single limited partner's disqualifying history contaminates every application. Diligence the cap table against the disclosure rules before the raise, not after.

Residency requirements — some states require in-state residency for some or all owners. Several such requirements have been challenged under the dormant Commerce Clause, with courts divided on whether the doctrine protects a market that is federally illegal. The results are inconsistent enough that a multi-state operator should treat the question as unsettled and structure accordingly.

Local approval is frequently the binding constraint. Many states permit municipalities to prohibit or limit cannabis businesses, and a state license is worthless without a local land use approval, conditional use permit, or host community agreement. Secure local approval before spending significantly on the state application.

Operational requirements to build for from day one: seed-to-sale track and trace integration; security — cameras with retention periods, alarms, access control, safes, transport protocols; inventory reconciliation on a defined cycle with variance thresholds; testing by licensed laboratories for potency, pesticides, heavy metals, residual solvents, and microbials; packaging and labeling with warnings, potency, batch identifiers, and child-resistant requirements; advertising restrictions, generally including audience-composition rules, prohibitions on health claims and on appeal to minors, and mandatory warnings; purchase limits and identification verification; and waste disposal protocols.

Enforcement. State agencies audit, and violations produce fines, suspension, and revocation. Because the license is the asset, a revocation is a total loss — which makes compliance spending the highest-return investment in the business and makes an acquirer's compliance diligence the most consequential part of any deal.

Taxes

§ 280E is the center of everything.

What it disallows: all ordinary and necessary business expense deductions under § 162 and credits, for a business trafficking in Schedule I or II controlled substances.

What survives: cost of goods sold. COGS is subtracted in computing gross income and is therefore not a "deduction." The planning consequence is that the more costs a business can properly capitalize into inventory, the lower its tax — and the rules governing what may be capitalized differ by license type.

Under the inventory rules, a reseller (a dispensary) may generally include only the invoice price of the goods plus transportation and necessary acquisition charges. A producer (a cultivator or manufacturer) uses the full absorption rules, capitalizing direct materials, direct labor, and a broad set of indirect production costs — including a share of rent, utilities, depreciation, quality control, and production supervision. A producer can absorb far more cost into COGS than a reseller can. That asymmetry is why vertical integration is so common in this industry, and it is a genuine, defensible tax planning point rather than an aggressive one.

What does not work: the argument that a business is not "trafficking" because it is state-legal, which has been rejected consistently; and, in most litigated cases, the attempt to allocate expenses to a separate non-cannabis trade or business, which succeeded in Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007), where a caregiving business was genuinely separate and substantial, and has failed repeatedly since where the separation was nominal. See Olive v. Commissioner, 792 F.3d 1146 (9th Cir. 2015). A separate business must be real: separate books, separate space, separate employees, separate customers, and independent economic substance.

Practical tax posture:

  • Engage a cannabis-experienced accountant before the first transaction. Cost accounting decisions made at the outset are extremely difficult to change later, and a § 471 inventory method adopted without thought will cost real money every year.
  • Document the cost allocation methodology contemporaneously and consistently.
  • Understand the entity choice. A C corporation caps the rate at 21 percent and does not pass disallowed deductions to owners. A pass-through entity passes phantom income to individual owners taxed at higher rates, which is frequently a worse outcome despite the general preference for pass-throughs.
  • Plan for cash tax. A profitable-looking business can be cash-flow negative after tax, and estimated payments must be funded.
  • State conformity varies. A number of states have decoupled from § 280E for state income tax purposes, permitting ordinary deductions on the state return. Confirm the position in each state.
  • Excise taxes — cultivation taxes, potency-based taxes, and retail excise taxes — are layered on and administered separately, with their own audit exposure.

Banking and payments

Why it is hard. A financial institution serving a cannabis business handles proceeds of federally unlawful activity, raising money laundering exposure under 18 U.S.C. §§ 1956 and 1957 and creating Bank Secrecy Act obligations. The consequence is not that banking is unavailable — hundreds of institutions serve the industry — but that it is expensive and conditional.

The FinCEN framework. FinCEN's 2014 guidance, BSA Expectations Regarding Marijuana-Related Businesses, does not authorize anything. It describes how an institution can meet its BSA obligations while serving these customers: conduct enhanced due diligence, including verifying state licensure, understanding the business, reviewing the license application, monitoring for red flags, and ongoing monitoring; and file suspicious activity reports in one of three categories — "Marijuana Limited" for a business the institution reasonably believes does not implicate enforcement priorities, "Marijuana Priority" where it may, and "Marijuana Termination" when the relationship ends.

Because a SAR must be filed on every such customer, servicing cost is high, and institutions pass it through as monthly fees that commonly run into the thousands of dollars.

Who serves the industry: primarily credit unions and community banks, with dedicated compliance programs. Expect to provide extensive documentation, to be examined continuously, and to have the relationship terminated on short notice if the institution's risk appetite or examiner posture changes. Maintain a relationship with a second institution.

Payments. The major card networks prohibit cannabis transactions, so retail is heavily cash. Workarounds have a poor history: cashless ATM arrangements, which mischaracterized transactions as ATM withdrawals, were shut down; "closed-loop" and cryptocurrency solutions vary in legitimacy. ACH and PIN debit solutions through cannabis-banking institutions exist and are the most defensible. Any payment solution that requires misdescribing the merchant or the transaction to a network is a fraud problem layered on top of a banking problem.

Cash handling consequences: armored transport, on-site safes and vaults, dual-control counting procedures, employee theft controls, and the § 6050I obligation to report receipt of more than $10,000 in cash in a trade or business on Form 8300. Structuring deposits to avoid reporting is a separate federal crime and has been charged against cannabis operators.

Insurance is available but limited: general liability, product liability, property, crop, and cargo coverage exist through surplus lines carriers at elevated pricing. Read the exclusions carefully — many policies contain a controlled substance exclusion that would swallow the coverage, and confirming its absence is the first thing to check.

Intellectual property

Trademarks. Federal registration requires lawful use in commerce. The USPTO refuses applications for goods and services that violate the Controlled Substances Act, and the TTAB has affirmed those refusals consistently. In re Morgan Brown, 119 U.S.P.Q.2d 1350 (TTAB 2016); In re JJ206, LLC, 120 U.S.P.Q.2d 1568 (TTAB 2016). See also TMEP § 907.

What actually works:

  • State trademark registration in each state of operation. Rights are narrow and remedies limited, but they exist and they are cheap.
  • Common law rights from actual use, which support unfair competition claims and provide priority in the geographic area of use.
  • Federal registration for lawful ancillary goods and services — apparel, papers and accessories that are not drug paraphernalia under 21 U.S.C. § 863, media, educational services, and consulting. A well-managed brand builds a federal portfolio around the periphery, which supports enforcement against infringers even though the core goods are unregistrable.
  • Hemp-derived products containing not more than 0.3 percent delta-9 THC on a dry weight basis are lawful under the 2018 Farm Bill, and registration is available for them — subject to the USPTO's examination of whether the goods comply with the Food, Drug, and Cosmetic Act, which is a separate and frequently fatal obstacle for ingestibles and for anything marketed with a health claim.
  • Intent-to-use applications filed in anticipation of legal change, recognizing that a statement of use will eventually be required.

Patents are available. The Patent Act contains no lawful-use requirement, and utility patents, plant patents, and plant variety protection certificates have been issued covering cannabis plants, extraction methods, formulations, and devices. Patent litigation in the industry has begun. The practical obstacle is prior art: decades of undocumented breeding are largely invisible to examiners, which makes issued patents both obtainable and vulnerable.

Trade secrets are the most important IP asset in practice — cultivar genetics, growing protocols, extraction parameters, and formulations. Protection requires reasonable secrecy measures: confidentiality agreements, access restrictions, marking, exit interviews, and documented protocols. Note that the federal Defend Trade Secrets Act requires that the trade secret be related to a product or service used in, or intended for use in, interstate or foreign commerce, which for a purely intrastate cannabis operation is a real jurisdictional question — making state trade secret law under the Uniform Trade Secrets Act the primary vehicle.

Copyright is available without a lawful-use limitation and protects packaging art, marketing materials, and software.

Contracts, disputes, and insolvency

Enforceability. Contracts with an unlawful object may be void as against public policy. Federal courts have refused to enforce cannabis contracts on illegality grounds in some cases and enforced them in others, and the trend has moved toward enforcement — particularly where the claim can be resolved without ordering an illegal act. State courts in legal states generally enforce them, most having concluded that state public policy favors enforcement of contracts within a state-authorized program.

Practical drafting responses: choose state court in a legal state and specify it; use arbitration with a seat in a legal state, which avoids the federal illegality problem and provides confidentiality, though enforcement of the award may return to a court; include severability and an express acknowledgment that the parties are aware of the federal status and intend enforcement notwithstanding it; and avoid remedies that would require a court to order the transfer of cannabis, in favor of monetary remedies and license-transfer mechanics that run through the regulator.

Bankruptcy is unavailable. United States Trustees move to dismiss cannabis cases, and courts have dismissed them, on the reasoning that a trustee cannot administer assets whose possession is a federal crime and that a plan cannot be funded by illegal activity. In re Way to Grow, Inc., 597 B.R. 111 (D. Colo. 2018). The bar has extended to businesses with substantial cannabis-derived revenue even where they do not touch the plant, and to individuals with cannabis income.

The alternatives: state-court receivership, which has become the standard tool and which several states have adapted specifically for cannabis licensees with regulator involvement; assignment for the benefit of creditors; negotiated workouts; and dissolution under state law. Lenders and investors should understand that the ordinary reorganization backstop does not exist, that a receiver's ability to operate depends on the regulator's willingness to permit it, and that collateral consisting of a license is not collateral in the ordinary sense, because most states prohibit transfer without approval and some prohibit pledging altogether.

Landlords and lenders face their own exposure: civil forfeiture of property used to facilitate a federal drug offense under 21 U.S.C. § 881, mortgage acceleration under standard compliance-with-law covenants, and insurance issues. Leases should address regulatory access, compliance obligations, an express acknowledgment of the use, and remedies keyed to license status.

Employment, products, and consumers

Employment law applies in full. Wage and hour, discrimination, leave, and safety statutes reach cannabis employers. OSHA enforcement in cultivation and extraction facilities has focused on hazardous chemicals, confined spaces, and combustible solvents. Union organizing is common, and several states require a labor peace agreement as a licensing condition.

Employee cannabis use is a rapidly changing area. A growing number of states restrict adverse employment action based on off-duty, off-premises use or on a positive test for non-psychoactive metabolites, with exceptions for safety-sensitive positions and federal contractors. Federal contractors remain subject to the Drug-Free Workplace Act, and Department of Transportation-regulated positions are subject to federal testing rules that do not recognize state legalization. Review testing policies state by state.

Product liability exposure is substantial and growing: contamination with pesticides, heavy metals, or microbials; mislabeled potency; failure to warn about intoxication, impairment, pediatric exposure, and interaction with pregnancy; and defective vaporizer hardware. Requirements: rigorous supplier qualification, batch testing with retained samples, a documented recall procedure with regulator notification, robust records, and coverage confirmed to include product liability without a controlled-substance exclusion.

Consumer protection. State UDAP statutes and the FTC reach health claims, potency claims, and organic or purity representations. Health claims are the single largest exposure — an unapproved claim that a product treats a disease makes it a drug under the FDCA and draws FDA warning letters, which the agency has issued in volume for CBD products.

Hemp and the intoxicating hemp problem

The 2018 Farm Bill removed hemp — cannabis with not more than 0.3 percent delta-9 THC on a dry weight basis — from the Controlled Substances Act, 7 U.S.C. § 1639o. It did not authorize hemp-derived products as foods, dietary supplements, or drugs; the FDA has maintained that CBD may not lawfully be added to food or marketed as a dietary supplement, and has requested a new regulatory pathway from Congress.

The gap that opened. Because the statutory definition is keyed to delta-9 THC concentration, products containing intoxicating cannabinoids that are not delta-9 — delta-8 THC, THCA (which converts to delta-9 on heating), HHC, THCP, and others — have been marketed as federally lawful hemp. Litigation has produced results favorable to that reading of the text in at least one circuit, while the DEA has taken the position that synthetically derived tetrahydrocannabinols remain controlled.

States have responded in every direction — banning intoxicating hemp products, regulating them through the cannabis system, imposing total-THC standards, setting age restrictions, or leaving them unregulated. Federal legislative fixes redefining hemp by total THC have been proposed repeatedly.

For an operator, the practical advice is unusually clear. This is the least stable corner of the industry. Products lawful today in a given state may be prohibited next session with short transition periods, inventory may become unsellable, and the arbitrage between the hemp and cannabis channels invites exactly the kind of enforcement that follows a public health event. Do not build a durable business on a definitional gap.

Conclusion

Every distinctive feature of cannabis business law traces to a single conflict, and the practical consequences are concrete.

§ 280E means the business is taxed on gross profit. Cost accounting is not a back-office function here; it is the largest determinant of after-tax return, and vertical integration is a tax strategy as much as an operational one. Rescheduling to Schedule III would end this, and would end far less than most operators expect.

The license is the asset, and it is held on conditions. Ownership disclosure, prior approval of transfers, local approval, and continuous operational compliance are the terms on which it is held, and revocation is a total loss with no bankruptcy backstop.

The federal-law disabilities require workarounds, not denial. Banking exists but is conditional and expensive. Trademark protection exists but must be built from state registrations, common law rights, and a federal portfolio around lawful peripheral goods. Contract enforcement exists but should be routed to state courts or arbitration in a legal state. Insolvency has no bankruptcy remedy, so receivership must be planned for in the loan documents rather than discovered at the default.

None of these makes the industry unworkable. All of them make it a field where structure decided at the outset determines what is possible later.

A worked example: buying a licensed dispensary

An operator agrees to acquire a single-location dispensary in a limited-license state for $6.2 million. Here is what the transaction actually involves, and where deals of this kind fail.

Structure. The deal is an equity purchase, not an asset purchase, because the license cannot be transferred as an asset — it belongs to the licensed entity, and moving it would require a new application in a market where no new licenses are being issued. That decision drives everything else: the buyer inherits every liability the entity has, including tax, employment, and regulatory exposure.

Regulatory approval is a condition precedent, not a post-closing formality. The buyer's owners must be disclosed, fingerprinted, and found suitable before the transfer is approved. In this state, approval takes four to seven months. The purchase agreement therefore has a long outside date, an interim operating covenant restricting what the seller may do in the meantime, an escrow, and a clear allocation of who bears the risk if approval is denied — which is the most negotiated term in the agreement.

Diligence that is specific to this industry. Beyond ordinary financial and legal diligence: the complete regulatory file including every notice of violation and its resolution; track-and-trace data reconciled against financial records, which is the fastest way to find both compliance problems and revenue misstatement; inventory reconciliation and variance history; testing records and any failed batches; the local approval and its conditions, including whether it survives a change of control; the lease and whether it permits assignment and cannabis use; § 280E tax positions and the inventory accounting method, because an aggressive COGS allocation is an assumed liability; cash handling procedures and Form 8300 filings; and the banking relationship, which frequently does not survive the transaction.

Two findings change the deal. First, the seller has been allocating a large share of rent and payroll to COGS on a methodology that will not survive examination, creating an estimated $900,000 of exposure across open years. This becomes a purchase price adjustment and a specific indemnity backed by escrow. Second, the local host community agreement contains a change-of-control provision requiring municipal consent, which nobody had identified. The municipality's consent becomes a second condition precedent and adds two months.

What the buyer cannot get. A representation that the business complies with federal law, because it does not. A title insurance policy that covers forfeiture risk. A financing commitment from a conventional lender. And a bankruptcy remedy if the acquisition fails — which is why the buyer negotiates a receivership provision and a license-transfer cooperation covenant into its own loan documents with the seller-financed portion of the price.

Closing mechanics. Funds move; the regulator's approval letter is a closing deliverable; the seller's principals resign and are removed from the license; the buyer's principals are added; the track-and-trace account is transferred; and the state is notified within whatever short window it requires. Missing that notification window is a violation on the first day of ownership, and it happens often enough to be worth a calendar entry.

Frequently asked questions

Can I deduct payroll? Only to the extent it is properly capitalized into cost of goods sold, which depends on whether the business is a producer or a reseller and on what the employee does. A budtender's wages are generally not recoverable; a trimmer's frequently are.

Would rescheduling to Schedule III make my business federally legal? No. It would end § 280E, which is worth a great deal. It would leave state-legal cannabis federally unlawful, because Schedule III substances require FDA approval and dispensing through registered channels.

Can I take my brand across state lines? Not the product. Interstate transport remains a federal offense, and it is also a state license violation nearly everywhere. Brands expand through licensing agreements with in-state licensees — which raises its own issues, because a licensor exercising too much control may become a disclosable owner in the licensee's state.

Can I get a federal trademark? Not for the plant-touching goods. Build the portfolio around lawful ancillary goods and services, register in each state, and preserve common law rights through documented use.

Can my company file for bankruptcy? Almost certainly not, and neither can an individual with substantial cannabis income. Plan for receivership instead, and write it into the loan documents before there is a default.

Can I fire an employee for a positive test? It depends on the state, on whether the position is safety-sensitive, and on whether the employer is a federal contractor or covered by DOT rules. A growing number of states protect off-duty use or prohibit reliance on metabolite testing. Review the policy jurisdiction by jurisdiction rather than nationally.

Is CBD legal? Hemp-derived CBD is not a controlled substance if the product meets the 0.3 percent delta-9 threshold. That does not make it lawful as a food additive or dietary supplement, which is a separate FDCA question the FDA has answered unfavorably, and it does not permit health claims.

What about delta-8 and THCA products? The most unstable corner of the field. The text of the Farm Bill supports the argument, the DEA disagrees as to synthetically derived cannabinoids, states have gone in every direction, and federal legislative fixes are repeatedly proposed. It is a business that can be legislated away between one session and the next.

How do multi-state operators actually work? Rarely as single consolidated companies. Because ownership rules, residency requirements, and license caps differ, most MSOs hold state operations through separate entities, sometimes with a management or IP licensing agreement running to a parent, and sometimes through structures in which the parent holds only an economic interest with no disclosable control. Those structures are examined closely by regulators, and the recurring question is whether the parent's actual influence exceeds what it disclosed. The safest posture is to disclose more than the rule appears to require, because an undisclosed controlling relationship discovered later is a suitability problem for every license in the group, not just the one at issue.

What is the single highest-return compliance investment? Inventory reconciliation against the state track-and-trace system, performed on a short cycle by someone whose job it is. Nearly every serious regulatory action against a licensee begins with an unexplained variance, and nearly every diligence process that kills a deal finds one. It is also the control that detects internal theft, which is the most common loss in a cash business, and it produces the records that support the cost accounting positions § 280E makes so valuable. One process, three returns.

Do I need cannabis-specific counsel, or will general business counsel do? Both, and the division matters. General counsel handles the entity, the lease, the employment policies, and the commercial agreements. Cannabis-specific counsel handles licensing, ownership disclosure, transfer approvals, and the regulator relationship — and reviews everything the general lawyer drafts for the industry-specific traps, of which the recurring ones are a management agreement that creates an undisclosed controlling interest, a convertible note that does the same, and an indemnity backed by nothing because the obligor cannot access bankruptcy protection or conventional credit.

Related articles

This article is provided for general informational purposes and does not constitute legal or tax advice. Cannabis remains a Schedule I controlled substance under federal law; state programs, hemp rules, and the federal rescheduling proceeding are all subject to change. Consult qualified counsel licensed in the relevant state before entering, financing, or transacting in this industry.